BRAF and melanoma: On the other hand, BRAF-mutated melanomas typically develop resistance to targeted monotherapy with B-Raf inhibitors within 1 year from commencement, and some of them are primarily resistant to the drugs (vemurafenib, dabrafenib) [28, 29].